Additional file 1 of New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01E and BCG-revaccination
Creators: name: Clark, Rebecca A.
name: Weerasuriya, Chathika K.
name: Portnoy, Allison
name: Mukandavire, Christinah
name: Quaife, Matthew
name: Bakker, Roel
name: Scarponi, Danny
name: Harris, Rebecca C.
name: Rade, Kirankumar
name: Mattoo, Sanjay Kumar
name: Tumu, Dheeraj
name: Menzies, Nicolas A.
name: White, Richard G.
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Biotechnology
subject: Sociology
subject: FOS: Sociology
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Science Policy
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Computational Biology

description: Additional file 1. The model structure, parameterisation, calibration, and simulation is described in detail, and additional epidemiological and economic results are provided. Figure S1.1--Tuberculosis natural history model structure. Figure S3.1--The estimated impact of the COVID-19 pandemic on tuberculosis incidence and mortality. Figure S3.2--Contribution of the private sector to reported case notifications. Figure S4.1--Vaccine structure for a NCI vaccine. Figure S4.2--Vaccine structure for a CI vaccine. Figure S4.3--Vaccine structure for an AI vaccine (protection does not build). Figure S4.4--Vaccine structure for an AI vaccine (protection builds). Figure S7.1--Tuberculosis incidence, disease prevalence, case notification and mortality rate trends. Figure S7.2--Tuberculosis infection prevalence, proportion retreated, access-to-care ratio and ratio of subclinical tuberculosis to total tuberculosis trends. Figure S7.3--Tuberculosis incidence and mortality rate trends. Figure S7.4--Tuberculosis disease and infection prevalence trends. Figure S7.5--Tuberculosis case notification and proportion retreated trends. Figure S7.6--Access-to-care ratio and the ratio of subclinical tuberculosis to all active tuberculosis trends. Figure S7.7--Posterior distributions for the 19 parameters varied during calibration. Figure S7.8--Tuberculosis incidence rate for the Strengthened Current Interventions baseline. Figure S8.1--Incidence and mortality rate reductions in 2050 for M72/AS01E scenarios. Figure S8.2--Cumulative tuberculosis cases, treatments, and deaths averted for M72/AS01E scenarios. Figure S8.3--Incidence and mortality rate reductions in 2050 for the BCG-revaccination scenarios. Figure S8.4--Cumulative tuberculosis cases, treatments, and deaths averted for BCG-revaccination scenarios. Figure S9.1--Efficiency frontiers for M72/AS01E Policy Scenarios. Figure S9.2--Comparison of ICERs for M72/AS01E Vaccine Characteristic and Coverage Scenarios. Figure S9.3--Basecase M72/AS01E scenario incremental discounted costs by year. Figure S9.4--Efficiency frontiers for BCG-revaccination Policy Scenarios. Figure S9.5--Comparison of ICERs for BCG-revaccination Vaccine Characteristic and Coverage Scenarios. Figure S9.6--Basecase BCG-revaccination scenario incremental discounted costs by year. Figure S9.7--Cost-effectiveness planes for the M72/AS01E and BCG-revaccination Basecase scenarios with the Strengthened Current interventions baseline. Table S2.1--India national model parameter values and sources. Table S2.2--How age varying parameters are operationalized. Table S2.3--Calculating treatment outcome parameter values for adults and children. Table S2.4--Calculation of treatment outcomes for India by year. Table S3.1--India national model calibration targets. Table S3.2--Incidence and mortality rate targets for all ages for 2025. Table S3.3--Number of incident tuberculosis cases by year in India. Table S3.4--The fraction of tuberculosis treatment notifications in India from the private sector and overall. Table S3.5--The WHO reported and adjusted tuberculosis case notification targets for India. Table S4.1--M72/AS01E and BCG-revaccination scenarios evaluated in the analysis. Table S4.2--Increase in protection for the number of vaccine courses. Table S5.1--Tuberculosis testing, diagnostic, and vaccination related cost inputs. Table S8.1--Health impact results for M72/AS01E scenarios. Table S8.2--Health impact results for BCG-revaccination scenarios. Table S9.1--Cost-effectiveness analysis for M72/AS01E Policy Scenarios. Table S9.2--Incremental DALYs averted, incremental costs averted, and ICERs from health-system and societal perspectives for M72/AS01E Vaccine Characteristic and Coverage Scenarios. Table S9.3--Total costs for the M72/AS01E scenarios from the health-system perspective. Table S9.4--Total costs for the M72/AS01E scenarios from the societal perspective. Table S9.5--Cost-effectiveness analysis for BCG-revaccination Policy Scenarios. Table S9.6--Incremental DALYs averted, incremental costs averted, and ICERs from health-system and societal perspectives for BCG-revaccination Vaccine Characteristic and Coverage Scenarios. Table S9.7--Total costs for the BCG-revaccination scenarios from the health-system perspective. Table S9.8--Total costs for the BCG-revaccination scenarios from the societal perspective.